Amicus Therapeutics (FOLD) Stock Forecast, Price Target & Predictions
FOLD Stock Forecast
Amicus Therapeutics stock forecast is as follows: an average price target of $15.00 (represents a 53.06% upside from FOLD’s last price of $9.80) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
FOLD Price Target
The average price target for Amicus Therapeutics (FOLD) is $15.00 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $15.00 to $15.00. This represents a potential 53.06% upside from FOLD's last price of $9.80.
FOLD Analyst Ratings
According to 7 Wall Street analysts, Amicus Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for FOLD stock is 0 'Strong Buy' (0.00%), 6 'Buy' (85.71%), 0 'Hold' (0.00%), 1 'Sell' (14.29%), and 0 'Strong Sell' (0.00%).
Amicus Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 17, 2024 | Tazeen Ahmad | Bank of America Securities | $15.00 | $12.03 | 24.69% | 53.06% |
| May 14, 2024 | Debjit Chattopadhyay | Guggenheim | $13.00 | $9.04 | 43.81% | 32.65% |
| May 09, 2024 | Jeffrey Hung | Morgan Stanley | $19.00 | $9.48 | 100.42% | 93.88% |
| Dec 19, 2023 | Jeffrey Hung | Morgan Stanley | $20.00 | $12.66 | 57.98% | 104.08% |
| May 10, 2021 | Salveen Richter | Goldman Sachs | $14.00 | $9.39 | 49.09% | 42.86% |
The latest Amicus Therapeutics stock forecast, released on Oct 17, 2024 by Tazeen Ahmad from Bank of America Securities, set a price target of $15.00, which represents a 24.69% increase from the stock price at the time of the forecast ($12.03), and a 53.06% increase from FOLD last price ($9.80).
Amicus Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 4 |
| Avg Price Target | - | $15.00 | $16.75 |
| Last Closing Price | $9.80 | $9.80 | $9.80 |
| Upside/Downside | -100.00% | 53.06% | 70.92% |
In the current month, the average price target of Amicus Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Amicus Therapeutics's last price of $9.80. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 23, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Oct 17, 2024 | Bank of America Securities | Buy | Buy | Hold |
| Oct 11, 2024 | Jefferies | Buy | Buy | Hold |
| Oct 11, 2024 | Cantor Fitzgerald | Underperform | Underperform | Hold |
| Sep 06, 2024 | Jefferies | Buy | Initialise | |
| Jul 22, 2024 | Cowen & Co. | Buy | Buy | Hold |
| May 30, 2024 | Wells Fargo | Overweight | Initialise | |
| May 14, 2024 | UBS | Buy | Buy | Hold |
| May 14, 2024 | Guggenheim | Underperform | Underperform | Hold |
| May 14, 2024 | Guggenheim | Buy | Upgrade | |
| May 09, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
| Dec 19, 2023 | Morgan Stanley | Overweight | Upgrade | |
| Feb 24, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Amicus Therapeutics's last stock rating was published by Cowen & Co. on Oct 23, 2024. The company gave FOLD a "Buy" rating, the same as its previous rate.
Amicus Therapeutics Financial Forecast
Amicus Therapeutics Revenue Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $103.50M | - | $86.27M | $88.10M | $81.69M | $80.73M | $78.72M | $82.15M | $79.55M | $77.41M | $66.40M | $70.57M | $67.44M |
| Avg Forecast | $258.00M | $242.00M | $229.00M | $221.00M | $222.00M | $207.00M | $194.00M | $181.00M | $181.62M | $167.35M | $153.74M | $142.00M | $147.37M | $134.93M | $121.21M | $111.19M | $114.35M | $102.30M | $89.83M | $83.18M | $86.31M | $84.21M | $85.87M | $77.18M | $83.41M | $80.11M | $73.16M | $71.70M | $69.56M | $64.81M |
| High Forecast | $267.25M | $250.67M | $237.21M | $228.92M | $229.96M | $214.42M | $200.95M | $187.49M | $188.13M | $173.35M | $159.26M | $145.85M | $149.27M | $135.01M | $121.21M | $111.19M | $114.43M | $102.30M | $93.05M | $86.16M | $89.41M | $84.21M | $85.87M | $77.18M | $83.41M | $80.11M | $73.16M | $71.70M | $69.56M | $64.81M |
| Low Forecast | $251.39M | $235.80M | $223.14M | $215.34M | $216.32M | $201.70M | $189.03M | $176.37M | $176.97M | $163.06M | $149.81M | $138.59M | $146.36M | $134.84M | $121.21M | $111.19M | $114.27M | $102.30M | $87.53M | $81.05M | $84.10M | $84.21M | $85.87M | $77.18M | $83.41M | $80.11M | $73.16M | $71.70M | $69.56M | $64.81M |
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 9 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | - | 1.04% | 1.02% | 0.97% | 0.94% | 1.02% | 0.98% | 0.99% | 1.06% | 0.93% | 1.01% | 1.04% |
Amicus Therapeutics's average Quarter revenue forecast for Dec 23 based on 7 analysts is $114.35M, with a low forecast of $114.27M, and a high forecast of $114.43M. FOLD's average Quarter revenue forecast represents a 10.48% increase compared to the company's last Quarter revenue of $103.50M (Sep 23).
Amicus Therapeutics EBITDA Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 9 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-29.21M | - | $-39.87M | $-56.09M | $-17.79M | $-51.54M | $-66.47M | $-70.61M | $-40.79M | $-36.98M | $-54.49M | $-62.77M | $-54.00M |
| Avg Forecast | $-177.10M | $-166.12M | $-157.19M | $-151.70M | $-152.39M | $-142.09M | $-133.17M | $-124.24M | $-124.67M | $-114.87M | $-105.54M | $-97.47M | $-101.16M | $-92.62M | $-83.21M | $-80.03M | $-78.49M | $-70.22M | $-61.66M | $-63.27M | $-50.33M | $-55.25M | $-56.34M | $-57.51M | $-54.72M | $-52.56M | $-48.00M | $-52.22M | $-45.64M | $-42.52M |
| High Forecast | $-172.57M | $-161.86M | $-153.17M | $-147.82M | $-148.49M | $-138.45M | $-129.76M | $-121.06M | $-121.48M | $-111.93M | $-102.83M | $-95.14M | $-100.47M | $-92.56M | $-83.21M | $-64.03M | $-78.44M | $-70.22M | $-60.08M | $-50.61M | $-40.26M | $-55.25M | $-56.34M | $-46.01M | $-54.72M | $-52.56M | $-48.00M | $-41.77M | $-45.64M | $-42.52M |
| Low Forecast | $-183.45M | $-172.07M | $-162.83M | $-157.14M | $-157.85M | $-147.18M | $-137.94M | $-128.70M | $-129.14M | $-118.99M | $-109.32M | $-100.12M | $-102.46M | $-92.68M | $-83.21M | $-96.04M | $-78.55M | $-70.22M | $-63.87M | $-75.92M | $-60.39M | $-55.25M | $-56.34M | $-69.02M | $-54.72M | $-52.56M | $-48.00M | $-62.66M | $-45.64M | $-42.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.42% | - | 0.63% | 1.11% | 0.32% | 0.91% | 1.16% | 1.29% | 0.78% | 0.77% | 1.04% | 1.38% | 1.27% |
undefined analysts predict FOLD's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Amicus Therapeutics's previous annual EBITDA (undefined) of $NaN.
Amicus Therapeutics Net Income Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 9 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-21.58M | - | $-52.93M | $-55.87M | $-33.29M | $-62.16M | $-85.26M | $-83.28M | $-50.29M | $-51.23M | $-65.66M | $-71.40M | $-64.01M |
| Avg Forecast | - | - | - | - | - | - | - | - | $25.53M | $16.51M | $10.14M | $-743.45K | $5.48M | $360.14K | $-16.73M | $-94.91M | $-17.62M | $-23.12M | $-34.72M | $-75.03M | $-59.35M | $-57.33M | $-64.06M | $-68.21M | $-47.50M | $-53.38M | $-65.65M | $-62.93M | $-69.77M | $-64.52M |
| High Forecast | - | - | - | - | - | - | - | - | $26.72M | $17.27M | $10.62M | $-424.83K | $8.77M | $376.92K | $-16.17M | $-75.93M | $-2.94M | $-22.35M | $-33.56M | $-60.02M | $-47.48M | $-57.33M | $-64.06M | $-54.57M | $-47.50M | $-53.38M | $-65.65M | $-50.34M | $-69.77M | $-64.52M |
| Low Forecast | - | - | - | - | - | - | - | - | $24.68M | $15.96M | $9.81M | $-1.17M | $1.10M | $348.15K | $-17.51M | $-113.89M | $-26.43M | $-24.20M | $-36.33M | $-90.03M | $-71.22M | $-57.33M | $-64.06M | $-81.85M | $-47.50M | $-53.38M | $-65.65M | $-75.51M | $-69.77M | $-64.52M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | - | 0.71% | 0.94% | 0.58% | 0.97% | 1.25% | 1.75% | 0.94% | 0.78% | 1.04% | 1.02% | 0.99% |
Amicus Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. FOLD's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Amicus Therapeutics SG&A Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 9 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $65.65M | - | $73.96M | $54.27M | $47.27M | $53.38M | $58.12M | $57.60M | $46.11M | $42.28M | $46.73M | $43.69M | $37.85M |
| Avg Forecast | $180.54M | $169.34M | $160.24M | $154.64M | $155.34M | $144.85M | $135.75M | $126.65M | $127.09M | $117.10M | $107.58M | $99.36M | $103.12M | $94.42M | $84.82M | $64.69M | $80.01M | $71.58M | $62.86M | $51.14M | $41.05M | $58.93M | $60.09M | $46.49M | $58.36M | $56.06M | $51.19M | $44.78M | $48.67M | $45.35M |
| High Forecast | $187.01M | $175.41M | $165.99M | $160.19M | $160.91M | $150.04M | $140.62M | $131.19M | $131.64M | $121.30M | $111.44M | $102.06M | $104.45M | $94.48M | $84.82M | $77.63M | $80.07M | $71.58M | $65.11M | $61.37M | $49.26M | $58.93M | $60.09M | $55.79M | $58.36M | $56.06M | $51.19M | $53.73M | $48.67M | $45.35M |
| Low Forecast | $175.91M | $165.00M | $156.14M | $150.68M | $151.37M | $141.14M | $132.28M | $123.41M | $123.83M | $114.10M | $104.83M | $96.98M | $102.42M | $94.36M | $84.82M | $51.76M | $79.96M | $71.58M | $61.25M | $40.91M | $32.84M | $58.93M | $60.09M | $37.19M | $58.36M | $56.06M | $51.19M | $35.82M | $48.67M | $45.35M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | - | 1.45% | 1.32% | 0.80% | 0.89% | 1.25% | 0.99% | 0.82% | 0.83% | 1.04% | 0.90% | 0.83% |
Amicus Therapeutics's average Quarter SG&A projection for Dec 23 is $80.01M, based on 7 Wall Street analysts, with a range of $79.96M to $80.07M. The forecast indicates a 21.88% rise compared to FOLD last annual SG&A of $65.65M (Sep 23).
Amicus Therapeutics EPS Forecast
| Dec 27 | Sep 27 | Jun 27 | Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 6 | 9 | 4 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | - | $-0.18 | $-0.19 | $-0.12 | $-0.21 | $-0.30 | $-0.31 | $-0.19 | $-0.19 | $-0.25 | $-0.28 | $-0.25 |
| Avg Forecast | - | - | - | - | - | - | - | - | $0.08 | $0.05 | $0.03 | $-0.00 | $0.02 | - | $-0.05 | $-0.06 | $-0.06 | $-0.08 | $-0.11 | $-0.14 | $-0.12 | $-0.19 | $-0.21 | $-0.25 | $-0.16 | $-0.18 | $-0.22 | $-0.24 | $-0.23 | $-0.21 |
| High Forecast | - | - | - | - | - | - | - | - | $0.09 | $0.06 | $0.03 | $-0.00 | $0.03 | - | $-0.05 | $-0.06 | $-0.01 | $-0.07 | $-0.11 | $-0.13 | $-0.11 | $-0.19 | $-0.21 | $-0.25 | $-0.16 | $-0.18 | $-0.22 | $-0.24 | $-0.23 | $-0.21 |
| Low Forecast | - | - | - | - | - | - | - | - | $0.08 | $0.05 | $0.03 | $-0.00 | - | - | $-0.06 | $-0.07 | $-0.09 | $-0.08 | $-0.12 | $-0.14 | $-0.12 | $-0.19 | $-0.21 | $-0.25 | $-0.16 | $-0.18 | $-0.22 | $-0.24 | $-0.23 | $-0.21 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | - | 1.32% | 1.62% | 0.64% | 1.00% | 1.18% | 1.98% | 1.08% | 0.88% | 1.03% | 1.20% | 1.18% |
According to undefined Wall Street analysts, Amicus Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to FOLD previous annual EPS of $NaN (undefined).
Amicus Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ARVN | Arvinas | $19.10 | $58.50 | 206.28% | Buy |
| LEGN | Legend Biotech | $34.68 | $89.60 | 158.36% | Buy |
| MLYS | Mineralys Therapeutics | $12.35 | $30.00 | 142.91% | Buy |
| KURA | Kura Oncology | $9.74 | $23.33 | 139.53% | Buy |
| MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
| RARE | Ultragenyx Pharmaceutical | $44.95 | $90.00 | 100.22% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| CYTK | Cytokinetics | $47.78 | $90.00 | 88.36% | Buy |
| DYN | Dyne Therapeutics | $26.16 | $49.00 | 87.31% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| FOLD | Amicus Therapeutics | $9.89 | $15.00 | 51.67% | Buy |
| DNLI | Denali Therapeutics | $23.22 | $35.00 | 50.73% | Buy |
| RVMD | Revolution Medicines | $45.16 | $65.67 | 45.42% | Buy |
| HRMY | Harmony Biosciences | $33.63 | $48.00 | 42.73% | Buy |
| BMRN | BioMarin Pharmaceutical | $67.19 | $94.43 | 40.54% | Buy |
| INCY | Incyte | $69.40 | $90.11 | 29.84% | Buy |
| AGIO | Agios Pharmaceuticals | $41.96 | $53.50 | 27.50% | Buy |
| BPMC | Blueprint Medicines | $96.48 | $122.60 | 27.07% | Buy |
| CRNX | Crinetics Pharmaceuticals | $55.37 | $69.00 | 24.62% | Buy |
| ARGX | argenx SE | $638.33 | $558.78 | -12.46% | Buy |